|
|
|
| Relationship between HPV subtype 33 positive and high-grade cervical lesions |
| LI Ran YIN Xiaojun▲ LI Ying |
| Department of Obstetrics and Gynecology, the Second Hospital of Kunshan, Jiangsu Province, Kunshan 215300, China |
|
|
|
Abstract Objective To study the correlation of high-risk human papillomavirus (HPV) subtype 33 positive and high-grade cervical lesions. Methods A total of 380 patients with cervical screening abnormalities, who received cervical biopsy in colposcopy clinic in the Second Hospital of Kunshan from January 2015 to January 2018 were collected and the relationship between HPV subtype 33 positive and high-grade cervical lesions were studied. Results All 380 women enrolled in this study, a total of 220 cases was cervical benign lesions, 20 cases were single type HPV33 infection, a total of 92 cases was LSIL, 12 cases were single type HPV33 infection, a total of 68 cases was LSIL, 20 cases were single type HPV33 infection. The infection rates of single type HPV33 infection in different groups were 9.1%, 13.3%, 29.4%. With the aggravation of cervical lesions, infection rates of single type HPV 33 gradually increased, the difference was statistically significant (χ2 = 18.097, P = 0.000). In patients of single type HPV 33 infection, the abnormality of TCT increased with the aggravation of cervical lesions, but the difference was not statistically significant (χ2 = 2.708, P = 0.258). Conclusion Patients with single type HPV 33 infection maybe receive colposcopy as soon as possible, and powerful interventions should be taken to block the progression of cervical diseases to cancer.
|
|
|
|
|
|
[1] Steben M，Duarte-Franco E. Human papilloma virus infection： epidemiology and pathophysiology [J]. Gynecologic Oncology，2007，107（2 Suppl 1）：2-5.
[2] Fujii T，Saito M，Iwata T，et al. Ancillary testing of liquid-based cytology specimens for identification of patients at high risk of cervical cancer [J]. Virchows Arch，2008，453（6）：545-555.
[3] Pankin DM，Pisani P，Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990 [J]. Int J Cancer，1999，80（6）：827-841.
[4] Vidart Aragón JA. New strategies for secondary prevention of cervical cancer [J]. An R Acad Nac Med（Madr），2012， 129（1）：137-146.
[5] Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin Number131：screening for cervical cancer [J]. Obstet Gynecol，2012，120（5）：1222-1238.
[6] Zur Hausen H，Meinhof W，Scheiber W，et al. Attempts to detect virus-secific DNA in humantumors.1Nucleic acid hybirdizations with complementary RNA of human wart virus [J]. Int J Cancer，1974，13（5）：650-656.
[7] Walboomers JM，Jacobs MV，Manos MM，et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide [J]. J Pathol，1999，189（1）：12-19.
[8] Bosch FX，Manos MM，Munoz N，et al. Prevalence of Human Papillomavirus in cervical cancer： a Word Perspective [J]. J National Cancer Inst，1995，87（11）：796-802.
[9] Chen W，Zheng R，Zhang S，et al. The incidences and mortalities of major cancers in China 2009 [J]. Chin J Cancer，2013，32（3）：106-112.
[10] 吴冬梅，郑怡真，刘倩，等.高级别宫颈上皮内瘤变中医证型分布及其与高危型HPV负荷量关系的研究[J].光明中医，2012，27（3）：489-491.
[11] 贾万钧，曹学全，甘梅富，等.宫颈病变中凋亡调控基因TRAIL及Caspase-3表达与HPV感染的相关性研究[J].中华医院感染学杂志，2011，21（22）：4677-4679.
[12] Ting J，Kruzikas DT，Smith JS，et al. A global review of age-specific and prevalence of cervical lesions [J]. Int J Gynecol Cancer，2010，20（7）：1244-1249.
[13] Louvanto K，Rintala MA，Syrjnen KJ，et al.Genotype-specific persistence of genital human papillomavirus（HPV）infections in women followed for 6 years in the Finnish Family HPV Study [J]. J Infect Dis，2010，202（3）：436.
[14] 甘钊杏，黄佩芬，陈莲芳，等.高危型HPV感染与宫颈癌前病变及宫颈癌的研究[J].中国当代医药，2013，20（9）：54-55.
[15] 施丽娜.高危型HPV检测联合TCT在宫颈癌筛查中的应用价值[J].中国妇幼保健，2010.25（6）：840-842.
[16] 张宏鹏.杨贷平.宫颈癌及癌前病变患者高危型HPV感染情况分析[J].国际检验医学杂志，2016，37（7）：119-120.
[17] 张倩，胡尚英，冯瑞梅，等.高危型人乳头状瘤病毒感染变化与宫颈癌及癌前病变发病风险的15年瞻队列随访研究[J].中华肿瘤杂志，2016，38（10）：328-330.
[18] Alemany L，de Sanjosé S，Tous S，et al. Time trends of human papillomavirus types in invasive cervical cancer from 1940 to 2007 [J]. Int J Cancer，2014，135（1）：88-95.
[19] Song SH，Lee JK，Oh MJ，et al. Persistent HPV infection after conization in patients with negative margins [J]. Gynecol Oncol，2006，101（3）：418-422.
[20] Serrano B，Alemany L，Ruiz PA，et al. Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries（Brazil，Mexico，India and China [J]. Cancer Epidemiol，2014，38（6）：748-749
[21] 杨英捷，赵健，李雪倩，等.人乳头状瘤病毒不同亚型感染与宫颈病变的相关性[J].中国妇产科临床杂志，2006， 7（4）：253-256.
[22] Clifford GM，Smith JS，Plummer M，et al. Human papillomavirus types in invasive cervical cancer worldwide ：a meta-analysis [J]. Br J Cancer，2003，88（1）：63-73.
[23] 乌兰娜，吴瑞芳，周艳秋，等.人乳头状瘤病毒基因亚型与宫颈病变的关系[J].中国妇产科临床杂志，2005，6（5）：346-350.
[24] 陶萍萍，卞美璐，欧华，等.导流杂交基因芯片技术在人乳头状瘤病毒检测中应用的研究[J]中华妇产科杂志，2006，41（1）：43-47.
[25] Harris SL，Thorne LB，Seaman WT. Association of P16 overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue [J]. Head Neck，2011，33（11）：1622-1627.
[26] Cuzick J，Clave C，Petry CH，et al. Overview of the European and north American studies on HPV testing in primary cervical screening [J]. Int J Cancer，2006，119（5）：1095-1101.
[27] 曹泽毅，沈铿，马彦彦，等.中华妇产科学（临床版）[M].北京：人民卫生出版社，2010：569，578-581. |
|
|
|
